Lanean...
Single and dual targeting of mutant EGFR with an allosteric inhibitor
Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding. In the present study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent, ca...
Gorde:
| Argitaratua izan da: | Cancer Discov |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6664433/ https://ncbi.nlm.nih.gov/pubmed/31092401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0903 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|